ROMIDEPSIN-REACH (Romidepsin)
romidepsin 10 mg injection [1 vial] (&) inert substance diluent [2 mL vial], 1 pack · INJECTION · PBS code 15405T
AUTHORITY_REQUIREDWhat it costs
AU$1223.27 PBS-determined price per pack
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2026-07-01.
- • Repeats: 8.
- • PBS program: IN.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Relapsed or chemotherapy refractory Peripheral T-cell Lymphoma
Continuing treatment
The condition must be relapsed or chemotherapy refractory; AND
Patient must not develop progressive disease whilst receiving PBS-subsidised treatment with this drug for this condition; AND
Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Relapsed or chemotherapy refractory Peripheral T-cell Lymphoma
Grandfather arrangement - Transitioning from non-PBS-subsidised treatment
Patient must have previously received non-PBS-subsidised treatment with this drug for this condition prior to 1 July 2026; AND
The condition must be relapsed or chemotherapy refractory; AND
Patient must have undergone appropriate prior front-line curative intent chemotherapy prior to commencing non-PBS-subsidised treatment with this drug for this condition; AND
Patient must not have developed progressive disease while receiving treatment with this drug for this condition; AND
The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication.
A patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the Continuing treatment criteria.
Sponsor: Reach Pharmaceuticals Pty Ltd ABN 25 623 897 183
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.